Shots:
- Vertex has entered into a definitive agreement to acquire Crinetics, incl. its assets Palsonify (paltusotine) & atumelnant, accelerating Vertex’s revenue growth and enhancing its long-term earnings profile
- As per the deal, Vertex to acquire Crinetics for $85/share in cash, representing the total equity value of ~$10B, or ~$8.8B net of estimated cash acquired
- Palsonify (QD, PO) is approved in the US & EU for adults with acromegaly, and is under global review, while atumelnant (QD, PO) is an ACTH receptor antagonist in P-III development for congenital adrenal hyperplasia
Ref: Businesswire | Image: Crinetics | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
